Stock prices remain underpinned by (1) central banks commitment to near-zero interest rates, (2) a V-shape recovery in a number of sectors, and (3) a medical treatment for COVID-19.

F&P Healthcare (FPH) has developed specialised expertise in heated humidification that forms the basis of its strong market position in the hospital and growing presence in homecare.

It has progressively widened its addressable market through new applications which is a key driver of an attractive, long-term, double-digit profit growth outlook.

The company is also benefiting from COVID-19 related demand, with some of its products recommended as a front-line therapy.

However, FPH is one of the most expensive global medical device companies (growth-adjusted and absolute).

While it is difficult to foresee a catalyst for a derating, particularly given near-term earnings momentum, we see better value for risk elsewhere.

Second quarter 2020 results from Mainfreight's (MFT) key global peers highlight material decline in freight demand as a result of COVID-19, but resilient margins across most industry segments.

MFT released its corresponding quarterly results at its Annual Shareholder Meeting on 30 July 2020, highlighting a stellar quarter, with revenue up +8% and pre-tax profit up +20% on the same period last year.

Its superior performance in the context of broader industry profitability decline highlights its best-in-class characteristics and continued strong growth potential.

MFT is trading at a one year forward PE of ~26x, a discount to its closest but significantly larger peers.

This webinar is presented Milford Asset Management.

➔ Learn other tips at  https://www.MaximSherstobitov.NZ/